Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses

Journal of Clinical Pathology

Volumn 69, Issue 8, 2016, Pages 706-712

  Kawai, Toshiaki ^a   Tominaga, Susumu ^a   Hiroi, Sadayuki ^a   Ogata, Sho ^a   Nakanishi, Kuniaki ^a   Kawahara, Kunimitsu ^b   Sonobe, Hiroshi ^c   Hiroshima, Kenzo ^d  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c CHUGOKU CENTRAL HOSPITAL   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; CD146 ANTIGEN; CLAUDIN 4; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN AE1; CYTOKERATIN AE3; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; GLUTAMATE ACETYLTRANSFERASE; MONOCLONAL ANTIBODY D2-40; THROMBOMODULIN; TRANSCRIPTION FACTOR PAX8; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CARCINOMA; CHROMOSOME 9P; DIFFERENTIAL DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; PERITONEAL MALIGNANT MESOTHELIOMA; PERITONEUM MESOTHELIOMA; PRIMARY PERITONEAL SEROUS CARCINOMA; PRIORITY JOURNAL; REACTIVE MESOTHELIAL HYPERPLASIA; SENSITIVITY AND SPECIFICITY; CYSTADENOCARCINOMA, SEROUS; GENETICS; HYPERPLASIA; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PERITONEUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PERITONEUM; YOUNG ADULT;

EID: 84983001925     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-203211     Document Type: Article

References (39)

1. Ministry of Health, Labour and Welfare. Vital statistics of Japan 2014. Tokyo: Ministry of Health, Labour and Welfare, 2014.
2. Takeshima Y, Inai K, Amatya VJ, et al. Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases. Lung Cancer 2009;66:191-7.
3. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 2006;19:34-48.
4. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010;34:627-35.
5. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999;189:251-7.
6. Ramael M, van den Bossche J, Buysse C, et al. Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J Pathol 1992;167:5-8.
7. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 1994;25:753-7.
8. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000;11:8-17.
9. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-20.
10. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011;35:878-82.
11. Sato A, Torii I, Okamura Y, et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010;23:1458-66.
12. Xiao S, Li D, Vijg J, et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511-15.
13. Prins J-B, Williamson KA, Kamp MMK, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998;75:649-53.
14. Hirao T, Bueno R, Chen CJ, et al. Alterations of the p16INK4 locus in human malignant mesothelial tumors. Carcinogenesis 2002;23:1127-30.
15. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003;99:51-6.
16. Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108-13.
17. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742-7.
18. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011;135:619-27.
19. Husain AN, Colby T, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. 2012 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 2012;136:1-21.
20. Smith MJ, Naylor B. A method for extracting ferruginous bodies from sputum and pulmonary tissue. Am J Clin Pathol 1972;58:250-4.
21. Kawai T, Hiroi S, Nakanishi K, et al. Lymphohistiocytoid mesothelioma of the pleura. Pathol Int 2010;60:566-74.
22. Kawai T, Kawashima K, Serizawa H, et al. Adenomatoid mesothelioma with intranuclear inclusion bodies: A case report with cytological and histological findings. Diagn Cytopathol 2014;42:436-40.
23. Travis W, Brambilla E, Burke AP, et al. Tumours of the pleura, WHO classification of tumours of the lung, pleura, thymus and heart. In: World Health Organization Classification of Tumours. William D. Travis, Elisabeth Brambilla, Allen P. Burke, Alexander Marx, Andrew G Nicholson Lyon: IARC, 2015:153-68.
24. Mensi C, Bonzini M, Macchione M, et al. Differences among peritoneal and pleural mesothelioma: data from the Lombardy Region Mesothelioma Register (Italy). Med Lav 2011;102:409-16.
25. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: A study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005;123:724-37.
26. Kadota K, Suzuki K, Sima CS, et al. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: A clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011;6:896-904.
27. Ordóñez NG. Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol 2012;25:1481-95.
28. Borczuk AC, Taub RN, Hesdorffer M, et al. p16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005;11:3303-8.
29. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathol 2002;40:237-44.
30. Ordóñez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 2005;36:1163-7.
31. Ordóñez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol 2013;26:553-62.
32. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-14.
33. Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum. Am J Clin Pathol 2006;125:67-76.
34. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: A useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31:1139-48.
35. Facchetti F, Lonardi S, Gentili F, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451:669-80.
36. Lonardi S, Manera C, Marucci R, et al. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol 2011;39:313-17.
37. Brockstedt U, Gulyas M, Dobra K, et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203-9.
38. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 2008;453:627-35.
39. Krasinskas AM, Bartlett DL, Cieply K, et al. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol 2010;23:531-8.